FDA Classifies Post-Surgical Phototherapy Devices as Class II

If you make or plan to bring to market a phototherapy device for reducing the appearance of acute post-surgical incisions, the FDA just drew a clearer line around what compliance looks like. On May 1, 2026, the agency published a final order in the Federal Register classifying these devices into Class II (Special Controls). That classification carries real obligations — and if you're already in this space, or thinking about entering it, the clock is running.

The lesson here is not just "know your device class." It's that FDA's De Novo pathway, which is what got us here, is increasingly the mechanism the agency uses to create new regulatory homes for emerging technologies — and manufacturers who understand that process are better positioned to move fast when these orders drop.

What Exactly Was Classified

The device type in question is the phototherapy device for reducing the appearance of acute post-surgical incisions. These are devices that use light energy — typically low-level laser or LED-based phototherapy — to address the cosmetic and healing characteristics of fresh surgical wounds in the post-operative period.

Prior to this order, no product code or classification regulation existed for this device type. That regulatory silence created a difficult situation for manufacturers: without a clear classification, 510(k) predicates were hard to identify, and the pathway to market was murkier than it needed to be.

The FDA resolved that ambiguity through its De Novo classification process under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act. The agency determined that Class II, with special controls, is sufficient to provide reasonable assurance of safety and effectiveness — meaning these devices don't need to meet the more burdensome premarket approval (PMA) standard of Class III.

That's genuinely good news for manufacturers. A Class II classification opens the 510(k) pathway for future devices of this type.

The Regulatory Mechanics: How De Novo Creates a Classification

This is worth understanding clearly, because it affects how you respond.

When FDA issues a De Novo order, two things happen simultaneously. First, the specific device that was the subject of the De Novo request gets authorization to market. Second, and more importantly for the industry at large, FDA establishes a new classification regulation — including a product code, a device definition, and the special controls that apply to the type.

That classification then becomes the predicate for future 510(k) submissions. Any manufacturer who wants to bring a substantially equivalent device to market can now point to this classification as their regulatory anchor.

According to FDA's Federal Register notice published May 1, 2026 (Docket No. FDA-2026-08497), the special controls applicable to this device type are incorporated directly into the codified language of the classification. Those controls are not optional guidance — they are regulatory requirements for any device that falls under this product type.

What the Special Controls Actually Require

Special controls are the mechanism FDA uses to manage risk in Class II devices. They go beyond the baseline requirements of general controls (registration, listing, labeling, QSR/Part 820 compliance) and impose device-specific technical requirements.

For phototherapy devices for post-surgical incision appearance, the special controls identified in this order address the specific risk profile of the device type. Based on the FDA's De Novo framework for similar light-based aesthetic and wound-care devices, manufacturers should expect special controls to include some combination of the following areas:

Manufacturers should pull the actual codified special controls language from the Federal Register order directly — the specific requirements are binding and supersede any generalizations I'm making here.

In my view, the clinical data requirement is where most manufacturers will face the steepest climb. "Reducing the appearance of acute post-surgical incisions" is a specific, outcome-oriented claim, and FDA will want to see evidence that the device actually does that — not just that it emits light safely.

Effective Date and What It Triggers

The final order was published May 1, 2026. De Novo classification orders are generally effective upon publication unless otherwise specified.

Here's what that effective date actually means in practice:

• The new product code is now active. FDA's device database will recognize devices of this type under the new classification.
• Future 510(k) submissions for substantially equivalent devices can now cite the De Novo-authorized device as a predicate.
• Any manufacturer currently marketing a device that falls within this device type description needs to evaluate whether their device is now captured by this classification — and whether they have the required marketing authorization.
• The special controls are now part of the codified regulatory requirements for this device type. If you're already on the market (through a prior authorization or through a gap in enforcement), you need to confirm your device meets these controls.

There is no grace period explicitly provided in De Novo classification orders for manufacturers to come into compliance with special controls. The expectation is that newly submitted 510(k)s will demonstrate conformance, and existing marketed devices should already meet the general and special control requirements applicable to their class.

What This Means for Your 510(k) Strategy

If you have a phototherapy device targeting post-surgical incision appearance and you haven't submitted a 510(k) yet, this order actually simplifies your path. You now have:

1. A clear predicate — the De Novo-authorized device
2. A defined special controls framework — which doubles as your technical file checklist
3. A product code — which means FDA reviewers will know exactly which classification lane your submission goes into

The 510(k) substantial equivalence analysis will turn on two questions: does your device have the same intended use, and does it have the same or different technological characteristics? If different, do those differences raise new safety or effectiveness questions?

For phototherapy devices, the technological differences most likely to trigger scrutiny are wavelength, power density, treatment duration, and delivery geometry. If your device departs from the De Novo device on any of these parameters, your submission needs to address why those differences don't introduce new risks.

One thing I tell clients at Certify Consulting: don't treat the special controls list as a checklist you complete after design. Build your design controls — your ISO 13485 design and development process under clause 7.3 — around the special controls from day one. Your design inputs should map directly to the special controls. Your verification and validation testing should generate the data that demonstrates conformance. If you do it that way, your technical file and your 510(k) essentially write themselves.

The ISO 13485 Connection

This classification order doesn't change your ISO 13485 obligations directly, but it absolutely affects how you implement them.

Under ISO 13485:2016 clause 7.3.3, design inputs must include applicable regulatory requirements. With this classification now in place, the special controls are regulatory requirements for devices of this type — which means they belong in your design input documentation from the beginning of any new product development.

Likewise, clause 7.3.6 (design and development verification) and clause 7.3.7 (design and development validation) need to be structured to generate evidence that your device conforms to those special controls. A validation plan that doesn't account for the clinical data requirements embedded in the special controls will have a gap that an auditor — or an FDA reviewer — will find.

For manufacturers who are ISO 13485 certified, this is also a trigger to review your regulatory requirements monitoring process. Clause 4.1 and clause 5.6 (management review) require that the organization stay current with applicable regulatory requirements. A De Novo classification order affecting your device type is exactly the kind of regulatory change that should show up in your management review inputs and trigger a documented evaluation of impact on your QMS.

A Broader Signal Worth Paying Attention To

FDA has been increasingly active in using De Novo to classify aesthetic, wellness, and light-based therapy devices that previously lived in regulatory gray zones. According to FDA's own data, the agency received and acted on a growing volume of De Novo requests over the past five years, and classification orders in the aesthetics and general surgery device space have accelerated alongside the consumer interest in non-invasive post-procedural care.

The phototherapy space specifically has seen significant market growth. The global photobiomodulation therapy market was valued at approximately $254 million in 2024 and is projected to grow at a compound annual growth rate of over 17% through 2030, according to industry market research. That growth is bringing more devices to market — and drawing more FDA attention to the category.

The practical implication is this: if you have a device in any adjacent light-therapy category — wound healing, scar treatment, anti-inflammatory applications — and you've been operating under a legacy product code or a broad general controls claim, now is a good time to reexamine your classification. FDA's increasing willingness to use De Novo to define new device types means the regulatory landscape around you may be shifting.

Practical Compliance Checklist

For manufacturers of phototherapy devices for post-surgical incision appearance — whether you're already on the market or preparing a new submission — here's where to focus:

Immediate steps (within 30 days): - Pull the full Federal Register order (FDA-2026-08497, published May 1, 2026) and read the codified special controls language - Evaluate whether your current device falls within the new device type definition - Confirm your current marketing authorization status and whether it covers this intended use

Near-term steps (30–90 days): - Map each special control to your existing design documentation and identify gaps - Review your ISO 13485 design input records to confirm regulatory requirements are captured - Assess whether your clinical data is sufficient to support the intended use claim under the new classification

If you're preparing a new 510(k): - Use the De Novo-authorized device as your primary predicate - Structure your substantial equivalence argument around the special controls framework - Engage with FDA early if your device has significant technological differences from the predicate

For manufacturers who want help navigating this kind of regulatory pivot, understanding the 510(k) substantial equivalence framework is a good place to start. And if you're building your QMS to support a first-time FDA submission, ISO 13485 implementation for medical device startups covers the design control foundations you'll need.

What Happens If You Don't Act

If your device falls under this classification and you're marketing it without 510(k) clearance, you're misbranded and adulterated under the FD&C Act. That's not a theoretical risk — FDA has been active on enforcement in the aesthetic device space, and De Novo classification orders often prompt a review of the market to identify devices operating without proper authorization.

The good news is that the 510(k) pathway is now well-defined for this device type. The predicate exists. The special controls tell you exactly what FDA wants to see. There's no legitimate reason to delay.

Last updated: 2026-05-08

Jared Clark, JD, MBA, PMP, CMQ-OE, CQA, CPGP, RAC is the Principal Consultant at Certify Consulting, where he has guided 200+ medical device manufacturers through FDA submissions and quality system compliance with a 100% first-time audit pass rate over 8+ years of practice.